Drugs / Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05035862 | Mar → Dec 2022 | asthma | Emory University | Terminated | No outcome recorded |
| Phase 1 | NCT04328714 | Dec 2021 → Jul 2022 | acute leukemia, myelodysplastic syndrome | Edwin Horwitz | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328714 ↗ |
| Known as | Interferon gamma-primed mesenchymal stromal cells (MSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035862 ↗ |
| Known as | γMSCs | “interferon γ (IFNγ) primed MSCs (γMSCs) potently suppress GVHD” NCT04328714 ↗1“interferon gamma-primed MSCs or γMSCs” NCT05035862 ↗ |
| Modality | Cell therapy | “this cell therapy may markedly reduce the regimen related toxicity of HCT” NCT04328714 ↗ |
| Route | Intravenous | “MSCs will be intravenously infused through a central line or a large bore peripheral IV” NCT04328714 ↗ |